Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Imagem de Miniatura
Arquivos
art_LOPES_Humanistic_and_Economic_Impact_of_Moderate_to_Severe_2019.PDF (499.37 KB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
LOPES, Nilceia
DIAS, Leticia L. S.
AZULAY-ABULAFIA, Luna
OYAFUSO, Luiza K. M.
SUAREZ, Maria Victoria
FABRICIO, Lincoln
KOBATA, Clarice Marie
CESTARI, Tania
GONTIJO, Bernardo
SABBAG, Cid Y.
Citação
ADVANCES IN THERAPY, v.36, n.10, p.2849-2865, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction Psoriasis is an immune-mediated, chronic, inflammatory disease, which has a substantial humanistic and economic burden. This study aimed to assess the impact of this disease on health-related quality of life (HRQoL), work productivity, and direct and indirect costs from a societal perspective among Brazilian patients. Methods This is a cross-sectional, observational, multicenter study, enrolling patients with moderate to severe plaque psoriasis according to physician evaluation. Data collection was performed from December 2015 to November 2016 through face-to-face interviews using a structured questionnaire and five standardized patient-reported outcomes instruments. Direct costs were estimated by multiplying the amount of resources used (12-month recall period) by the corresponding unit cost. Indirect costs were grouped in two time horizons: annual costs (income reduction and absenteeism) and lifetime costs (demission and early retirement). Results A total of 188 patients with moderate to severe plaque psoriasis were included, with mean age of 48.0 (SD 13.1). ""Anxiety and depression"" and ""pain and discomfort"" were the most impaired dimensions, according to the EuroQol Five-Dimension-Three-Level (EQ-5D-3L). The highest effect was found for ""symptoms and feelings"" [mean (SD) 2.4 (1.7)] Dermatology Life Quality Index (DLQI) subscale. Psoriatic arthritis (PsA) presence and biologic-naive status were associated with worse HRQoL. Presenteeism was more frequent than absenteeism, according to the Work Productivity and Activity Impairment questionnaire-General Health (WPAI-GH) [17.4% vs. 6.3%], while physical demands and time management were the most affected Work Limitations Questionnaire (WLQ) subscales [means (SD) 23.5 (28.5) and 17.7 (24.9), respectively]. The estimated annual cost per patient was USD 4034. Direct medical costs accounted for 87.7% of this estimate, direct non-medical costs for 2.4%, and indirect costs for 9.9%. Conclusions Results evidenced that moderate to severe plaque psoriasis imposes substantial costs to society. Our data showed that this disease negatively affects both work productivity and HRQoL of Brazilian patients. Subgroups with PsA and biologic-naive patients presented lower HRQoL, showing the impact of this comorbidity and the relevance of biologics in psoriasis treatment. Funding Novartis Biociencias S.A.
Palavras-chave
Cost of illness, Dermatology, Productivity, Psoriasis, Quality of Life
URI
https://observatorio.fm.usp.br/handle/OPI/34166
Referências
  1. Balogh O, 2014, EUR J HEALTH ECON, V15, pS101, DOI 10.1007/s10198-014-0599-z
  2. Boccuzzi SJ, 2003, CONTEMP CARDIOL, P63
  3. Boehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7
  4. Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6
  5. Burgos-Pol R, 2016, ACTAS DERMO-SIFILOGR, V107, P577, DOI 10.1016/j.ad.2016.04.018
  6. Carrascosa JM, 2006, J EUR ACAD DERMATOL, V20, P840, DOI 10.1111/j.1468-3083.2006.01659.x
  7. Chan B, 2009, J CUTAN MED SURG, V13, P192, DOI 10.2310/7750.2009.08068
  8. Ciconelli Rozana Mesquita, 2006, Sao Paulo Med. J., V124, P325, DOI 10.1590/S1516-31802006000600005
  9. de Korte J, 2004, J INVEST DERM SYMP P, V9, P140, DOI 10.1046/j.1087-0024.2003.09110.x
  10. DiBonaventura M, 2018, AN BRAS DERMATOL, V93, P197, DOI 10.1590/abd1806-4841.20186069
  11. Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
  12. Driessen RJB, 2010, BRIT J DERMATOL, V162, P1324, DOI 10.1111/j.1365-2133.2010.09693.x
  13. FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x
  14. Goncalves DA, 2014, CAD SAUDE PUBLICA, V30, P623, DOI 10.1590/0102-311X00158412
  15. Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4
  16. Horn EJ, 2007, J AM ACAD DERMATOL, V57, P963, DOI 10.1016/j.jaad.2007.07.023
  17. Kossakowska MM, 2010, J EUR ACAD DERMATOL, V24, P429, DOI 10.1111/j.1468-3083.2009.03432.x
  18. Lerner D, 2001, MED CARE, V39, P72, DOI 10.1097/00005650-200101000-00009
  19. Levy AR, 2012, INT J DERMATOL, V51, P1432, DOI 10.1111/j.1365-4632.2011.05359.x
  20. Liang Y, 2017, CURR OPIN IMMUNOL, V49, P1, DOI 10.1016/j.coi.2017.07.007
  21. Martins BDL, 2008, AN BRAS DERMATOL, V83, P39, DOI 10.1590/S0365-05962008000100005
  22. Martins Gladys Aires, 2004, An. Bras. Dermatol., V79, P521, DOI 10.1590/S0365-05962004000500002
  23. Meyer N, 2010, J EUR ACAD DERMATOL, V24, P1075, DOI 10.1111/j.1468-3083.2010.03600.x
  24. Michalek IM, 2017, J EUR ACAD DERMATOL, V31, P205, DOI 10.1111/jdv.13854
  25. Moller AH, 2015, PATIENT-RELAT OUTCOM, V6, P167, DOI 10.2147/PROM.S81428
  26. Moradi M, 2015, ARCH IRAN MED, V18, P153, DOI 0151803/AIM.004
  27. Norris D, 2017, J DERMATOL TREAT, V28, P731, DOI 10.1080/09546634.2017.1329501
  28. Ogdie A, 2015, RHEUM DIS CLIN N AM, V41, P545, DOI 10.1016/j.rdc.2015.07.001
  29. Puig L, 2015, J DERMATOL TREAT, V26, P7, DOI 10.3109/09546634.2013.860209
  30. Reilly Associates, 2016, WPAI SCOR
  31. REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006
  32. Romiti R, 2018, J DERMATOLOG, V17, P1
  33. Romiti R, 2017, INT J DERMATOL, V56, pE167, DOI 10.1111/ijd.13604
  34. Rosen CF, 2012, RHEUMATOLOGY, V51, P571, DOI 10.1093/rheumatology/ker365
  35. Santos M, 2016, MED DECIS MAKING, V36, P253, DOI 10.1177/0272989X15613521
  36. Schaefer CP, 2015, J AM ACAD DERMATOL, V73, P585, DOI 10.1016/j.jaad.2015.06.049
  37. Snaith R, 1993, QUAL LIFE NEWSLETTER, V6, P5
  38. Sojevic Timotijevic Z, 2013, J DERMATOL, V40, P797, DOI 10.1111/1346-8138.12201
  39. Tang K, 2011, ARTHRIT CARE RES, V63, pS337, DOI 10.1002/acr.20633
  40. Tejada CD, 2011, AN BRAS DERMATOL, V86, P1113, DOI 10.1590/S0365-05962011000600008
  41. Vanderpuye-Orgle J, 2015, J AM ACAD DERMATOL, V72, P961, DOI 10.1016/j.jaad.2015.02.1099
  42. White D, 1999, BRIT J PSYCHIAT, V175, P452, DOI 10.1192/bjp.175.5.452
  43. WILLIAMS A, 1990, HEALTH POLICY, V16, P199
  44. Wu Y, 2009, AM J CLIN DERMATOL, V10, P407, DOI 10.2165/11310440-000000000-00000
  45. ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/50